Von Willebrand Disease in the elderly: clinical perspectives

John Chapin Department of Hematology, Shire, Lexington, MA, USA Abstract: Von Willebrand disease (VWD) is an inherited bleeding disorder that affects up to 1% of the population. In most cases, VWD results from a mutation in the von Willebrand Factor (VWF) gene, which alters the amount and function o...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autor principal:	Chapin J
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2018
Materias:	von Willebrand disease acquired von Willebrand syndrome bleeding disorders aging Geriatrics RC952-954.6
Acceso en línea:	https://doaj.org/article/cbfdef657f834a9cba865c61f6bf9c47
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:cbfdef657f834a9cba865c61f6bf9c47
record_format	dspace
spelling	oai:doaj.org-article:cbfdef657f834a9cba865c61f6bf9c472021-12-02T01:38:15ZVon Willebrand Disease in the elderly: clinical perspectives1178-1998https://doaj.org/article/cbfdef657f834a9cba865c61f6bf9c472018-08-01T00:00:00Zhttps://www.dovepress.com/von-willebrand-disease-in-the-elderly-clinical-perspectives-peer-reviewed-article-CIAhttps://doaj.org/toc/1178-1998John Chapin Department of Hematology, Shire, Lexington, MA, USA Abstract: Von Willebrand disease (VWD) is an inherited bleeding disorder that affects up to 1% of the population. In most cases, VWD results from a mutation in the von Willebrand Factor (VWF) gene, which alters the amount and function of VWF, a key glycoprotein in both primary and secondary hemostasis. A comprehensive analysis of patients with VWD should include VWF activity, antigen levels, platelet function, and a careful bleeding history. Treatment options include antifibrinolytics, desmopressin, and VWF replacement therapy. VWF levels fluctuate due to age, stress, environmental exposures, and pharmacologic treatment. Treatment guidelines exist to treat and prevent bleeding for patients undergoing surgery and medical procedures, but often these must be reevaluated in the setting of age-related comorbidities including cardiovascular events, venous thrombosis, and malignancy. In addition, many age-related complications are associated with a secondary acquired von Willebrand syndrome (AVWS), including malignancies, hypothyroidism, cardiovascular diseases, and cardiac replacement devices. The current literature is limited by a lack of older patients in clinical trials. Larger studies are needed to determine if age-related comorbidities affect VWD patients at different frequencies than the general elderly population. There is also a significant need for registry-based studies to evaluate many age-related comorbidities in VWD patients. Keywords: von Willebrand disease, acquired von Willebrand syndrome, bleeding disorders, agingChapin JDove Medical Pressarticlevon Willebrand diseaseacquired von Willebrand syndromebleeding disordersagingGeriatricsRC952-954.6ENClinical Interventions in Aging, Vol Volume 13, Pp 1531-1541 (2018)
institution	DOAJ
collection	DOAJ
language	EN
topic	von Willebrand disease acquired von Willebrand syndrome bleeding disorders aging Geriatrics RC952-954.6
spellingShingle	von Willebrand disease acquired von Willebrand syndrome bleeding disorders aging Geriatrics RC952-954.6 Chapin J Von Willebrand Disease in the elderly: clinical perspectives
description	John Chapin Department of Hematology, Shire, Lexington, MA, USA Abstract: Von Willebrand disease (VWD) is an inherited bleeding disorder that affects up to 1% of the population. In most cases, VWD results from a mutation in the von Willebrand Factor (VWF) gene, which alters the amount and function of VWF, a key glycoprotein in both primary and secondary hemostasis. A comprehensive analysis of patients with VWD should include VWF activity, antigen levels, platelet function, and a careful bleeding history. Treatment options include antifibrinolytics, desmopressin, and VWF replacement therapy. VWF levels fluctuate due to age, stress, environmental exposures, and pharmacologic treatment. Treatment guidelines exist to treat and prevent bleeding for patients undergoing surgery and medical procedures, but often these must be reevaluated in the setting of age-related comorbidities including cardiovascular events, venous thrombosis, and malignancy. In addition, many age-related complications are associated with a secondary acquired von Willebrand syndrome (AVWS), including malignancies, hypothyroidism, cardiovascular diseases, and cardiac replacement devices. The current literature is limited by a lack of older patients in clinical trials. Larger studies are needed to determine if age-related comorbidities affect VWD patients at different frequencies than the general elderly population. There is also a significant need for registry-based studies to evaluate many age-related comorbidities in VWD patients. Keywords: von Willebrand disease, acquired von Willebrand syndrome, bleeding disorders, aging
format	article
author	Chapin J
author_facet	Chapin J
author_sort	Chapin J
title	Von Willebrand Disease in the elderly: clinical perspectives
title_short	Von Willebrand Disease in the elderly: clinical perspectives
title_full	Von Willebrand Disease in the elderly: clinical perspectives
title_fullStr	Von Willebrand Disease in the elderly: clinical perspectives
title_full_unstemmed	Von Willebrand Disease in the elderly: clinical perspectives
title_sort	von willebrand disease in the elderly: clinical perspectives
publisher	Dove Medical Press
publishDate	2018
url	https://doaj.org/article/cbfdef657f834a9cba865c61f6bf9c47
work_keys_str_mv	AT chapinj vonwillebranddiseaseintheelderlyclinicalperspectives
_version_	1718402985143304192

Von Willebrand Disease in the elderly: clinical perspectives

Ejemplares similares